| Symbol | CNTX |
|---|---|
| Name | CONTEXT THERAPEUTICS INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 2001 MARKET STREET, UNIT NO 15,SUITE 3915, PHILADELPHIA, Pennsylvania, 19103, United States |
| Telephone | +1 267 225-7416 |
| Fax | — |
| — | |
| Website | https://www.contexttherapeutics.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001842952 |
| Description | Context Therapeutics Inc. (Nasdaq: CNTX) is a biopharmaceutical company advancing T cell engaging ("TCE") bispecific antibodies for solid tumors. Context is building an innovative portfolio of TCE bispecific therapeutics with multiple products in development, including two clinical-stage assets. Context is headquartered in Philadelphia. Additional info from NASDAQ: |
New Form DEFA14A - Context Therapeutics Inc. <b>Filed:</b> 2026-04-28 <b>AccNo:</b> 0001628280-26-027942 <b>Size:</b> 1 MB
Read moreNew Form DEF 14A - Context Therapeutics Inc. <b>Filed:</b> 2026-04-28 <b>AccNo:</b> 0001628280-26-027928 <b>Size:</b> 2 MB
Read moreNew Form PRE 14A - Context Therapeutics Inc. <b>Filed:</b> 2026-04-17 <b>AccNo:</b> 0001628280-26-025776 <b>Size:</b> 2 MB
Read more(80% Positive) CONTEXT THERAPEUTICS INC. (CNTX) Provides Update on expected for solid tumors
Read moreContext Therapeutics Announces CTIM-76 Receives FDA Fast Track Designation for the Treatment of Platinum-Resistant Ovarian Cancer
Read more(90% Positive) CONTEXT THERAPEUTICS INC. (CNTX) Provides Update on reflected for such are reasonable
Read moreContext Therapeutics Reports Full Year 2025 Operating and Financial Results
Read moreNew Form S-8 - Context Therapeutics Inc. <b>Filed:</b> 2026-03-23 <b>AccNo:</b> 0001628280-26-020575 <b>Size:</b> 248 KB
Read moreContext Therapeutics Announces Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2026
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT07545122 | A Phase 1a/1b, First-Time-in-Human Study of CT-202, a Nectin-4 Directed Bispeci… | Phase1 | Triple Negative Breast Cancer (TNBC) | Not_Yet_Recruiting | 2026-09-01 | 2030-01-01 | ClinicalTrials.gov |
| NCT07270601 | Development of a Quantifiable Ultrasound Biomarker for Hepatic Steatosis | Na | MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease | Recruiting | 2025-11-17 | 2026-12-31 | ClinicalTrials.gov |
| NCT06756035 | CT-95 in Advanced Cancers Associated With Mesothelin Expression | Phase1 | Mesothelin-Expressing Tumors | Recruiting | 2025-03-31 | 2028-12-01 | ClinicalTrials.gov |
| NCT06515613 | A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other … | Phase1 | Platinum-resistant Ovarian Cancer | Recruiting | 2024-07-10 | 2028-04-30 | ClinicalTrials.gov |
| NCT05885984 | Acceptance and Commitment Therapy on Fatigue Interference in Patients With Adva… | Na | Lung Cancer | Unknown | 2023-07-01 | 2024-01-01 | ClinicalTrials.gov |
| NCT06938711 | A Rollover Protocol of Elacestrant, in Combination With Onapristone, for Patien… | Phase1 | Breast Cancer | Withdrawn | 2023-06-01 | 2023-12-01 | ClinicalTrials.gov |
| NCT05618613 | Study of Elacestrant in Combination With Onapristone in Patients With Advanced … | Phase1 | Breast Cancer | Terminated | 2022-12-02 | 2023-06-23 | ClinicalTrials.gov |
| NCT05481762 | Evaluation of Contextflow DETECT Lung CT Nodule Detection Software in Chest CT … | — | Lung Cancer | Completed | 2022-04-01 | 2022-10-30 | ClinicalTrials.gov |
| NCT04738292 | Onapristone and Fulvestrant for ER+ HER2- Metastatic Breast Cancer After Endocr… | Phase2 | ER-positive Breast Cancer | Terminated | 2021-10-05 | 2023-05-15 | ClinicalTrials.gov |
| NCT04872608 | A Study of Letrozole, Palbociclib, and Onapristone ER in People With Metastatic… | Phase1 | Metastatic Breast Cancer | Withdrawn | 2021-09-09 | 2023-04-25 | ClinicalTrials.gov |
| NCT04719273 | Onapristone and Anastrozole for the Treatment of Refractory Hormone Receptor Po… | Phase2 | Refractory Endometrial Adenocarcinoma | Active_Not_Recruiting | 2021-01-28 | 2025-12-31 | ClinicalTrials.gov |
| NCT03909152 | A Study of Onapristone ER Alone Or In Combination With Anastrozole in Gynecolog… | Phase2 | Granulosa Cell Ovarian Cancer | Completed | 2019-05-02 | 2024-09-03 | ClinicalTrials.gov |
| NCT02761681 | Mindfulness and Acceptance Applied in Colleges Through Web-Based Guided Self-He… | Na | Mental Health | Completed | 2015-04-01 | 2019-06-01 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Control Web-based guided self-help | Other | Approved | Mental Health | COMPLETED | NCT02761681 |
| ACT-CL Web-based guided self-help | Other | Approved | Mental Health | COMPLETED | NCT02761681 |
| Control Web-based guided self-help | Other | Approved | Mental Health | COMPLETED | NCT02761681 |
| ACT-CL Web-based guided self-help | Other | Approved | Mental Health | COMPLETED | NCT02761681 |
| Aided read with contextflow DETECT Lung CT | Other | Preclinical | Lung Cancer | COMPLETED | NCT05481762 |
| Aided read with contextflow DETECT Lung CT | Other | Preclinical | Lung Cancer | COMPLETED | NCT05481762 |
| Onapristone ER | Other | Phase PHASE1 | Metastatic Breast Cancer | WITHDRAWN | NCT04872608 |
| Palbociclib | Other | Phase PHASE1 | Metastatic Breast Cancer | WITHDRAWN | NCT04872608 |
| Letrozole | Other | Phase PHASE1 | Metastatic Breast Cancer | WITHDRAWN | NCT04872608 |
| Health education | Other | Approved | Lung Cancer | UNKNOWN | NCT05885984 |
| Acceptance and Commitment Therapy (ACT) plus health education | Drug | Approved | Lung Cancer | UNKNOWN | NCT05885984 |
| Health education | Other | Approved | Lung Cancer | UNKNOWN | NCT05885984 |
| Acceptance and Commitment Therapy (ACT) plus health education | Drug | Approved | Lung Cancer | UNKNOWN | NCT05885984 |
| Health education | Other | Approved | Lung Cancer | UNKNOWN | NCT05885984 |
| Acceptance and Commitment Therapy (ACT) plus health education | Drug | Approved | Lung Cancer | UNKNOWN | NCT05885984 |
| Fulvestrant | Other | Phase PHASE2 | ER-positive Breast Cancer | TERMINATED | NCT04738292 |
| Onapristone | Other | Phase PHASE2 | ER-positive Breast Cancer | TERMINATED | NCT04738292 |
| Progesterone Receptor Positive ( PGR Positive; PR Positive) | Other | Phase PHASE2 | Refractory Endometrial Adenocarcinoma | ACTIVE_NOT_RECRUITING | NCT04719273 |
| Estrogen Receptor Positive (Positive Estrogen Receptor; ESR Positive; ESR1 Positive; ER Positive; Estrogen Receptor Alpha Positive) | Other | Phase PHASE2 | Refractory Endometrial Adenocarcinoma | ACTIVE_NOT_RECRUITING | NCT04719273 |
| Questionnaire Administration | Other | Phase PHASE2 | Refractory Endometrial Adenocarcinoma | ACTIVE_NOT_RECRUITING | NCT04719273 |
| Quality-of-Life Assessment | Other | Phase PHASE2 | Refractory Endometrial Adenocarcinoma | ACTIVE_NOT_RECRUITING | NCT04719273 |
| Anastrozole | Other | Phase PHASE2 | Refractory Endometrial Adenocarcinoma | ACTIVE_NOT_RECRUITING | NCT04719273 |
| Extended-release Onapristone | Other | Phase PHASE2 | Refractory Endometrial Adenocarcinoma | ACTIVE_NOT_RECRUITING | NCT04719273 |
| Onapristone | Other | Phase PHASE1 | Breast Cancer | WITHDRAWN | NCT06938711 |
| Elacestrant | Other | Phase PHASE1 | Breast Cancer | WITHDRAWN | NCT06938711 |
| Onapristone | Other | Phase PHASE1 | Breast Cancer | TERMINATED | NCT05618613 |
| Elacestrant | Other | Phase PHASE1 | Breast Cancer | TERMINATED | NCT05618613 |
| Onapristone ER + Anastrozole | Other | Phase PHASE2 | Granulosa Cell Ovarian Cancer | COMPLETED | NCT03909152 |
| Onapristone ER | Other | Phase PHASE2 | Granulosa Cell Ovarian Cancer | COMPLETED | NCT03909152 |
| CT-95 | Other | Phase PHASE1 | Mesothelin-Expressing Tumors | RECRUITING | NCT06756035 |
| Philips 3T Ingenia Elition | Other | Approved | MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease | RECRUITING | NCT07270601 |
| EchoSense FibroScan | Other | Approved | MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease | RECRUITING | NCT07270601 |
| Philips EPIQ Elite | Other | Approved | MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease | RECRUITING | NCT07270601 |
| Verasonics NXT Data Acquisition System | Other | Approved | MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease | RECRUITING | NCT07270601 |
| Philips 3T Ingenia Elition | Other | Approved | MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease | RECRUITING | NCT07270601 |
| EchoSense FibroScan | Other | Approved | MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease | RECRUITING | NCT07270601 |
| Philips EPIQ Elite | Other | Approved | MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease | RECRUITING | NCT07270601 |
| Verasonics NXT Data Acquisition System | Other | Approved | MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease | RECRUITING | NCT07270601 |
| CTIM-76 | Other | Phase PHASE1 | Platinum-resistant Ovarian Cancer | RECRUITING | NCT06515613 |
| CT-202 | Other | Phase PHASE1 | Triple Negative Breast Cancer (TNBC) | NOT_YET_RECRUITING | NCT07545122 |
| CT-202 | Other | Phase PHASE1 | Triple Negative Breast Cancer (TNBC) | NOT_YET_RECRUITING | NCT07545122 |
| CT-202 | Other | Phase PHASE1 | Triple Negative Breast Cancer (TNBC) | NOT_YET_RECRUITING | NCT07545122 |
| CT-202 | Other | Phase PHASE1 | Triple Negative Breast Cancer (TNBC) | NOT_YET_RECRUITING | NCT07545122 |
| CT-202 | Other | Phase PHASE1 | Triple Negative Breast Cancer (TNBC) | NOT_YET_RECRUITING | NCT07545122 |
| CT-202 | Other | Phase PHASE1 | Triple Negative Breast Cancer (TNBC) | NOT_YET_RECRUITING | NCT07545122 |
| CT-202 | Other | Phase PHASE1 | Triple Negative Breast Cancer (TNBC) | NOT_YET_RECRUITING | NCT07545122 |
| CT-202 | Other | Phase PHASE1 | Triple Negative Breast Cancer (TNBC) | NOT_YET_RECRUITING | NCT07545122 |
| CT-95 | DRUG | Phase PHASE1 | Mesothelin-Expressing Tumors | RECRUITING | NCT06756035 |
| CTIM-76 | DRUG | Phase PHASE1 | Platinum-resistant Ovarian Cancer | RECRUITING | NCT06515613 |
| Elacestrant | DRUG | Phase PHASE1 | Breast Cancer | WITHDRAWN | NCT06938711 |
| Palbociclib | DRUG | Phase PHASE1 | Metastatic Breast Cancer | WITHDRAWN | NCT04872608 |
| Letrozole | DRUG | Phase PHASE1 | Metastatic Breast Cancer | WITHDRAWN | NCT04872608 |
| Fulvestrant | DRUG | Phase PHASE2 | ER-positive Breast Cancer | TERMINATED | NCT04738292 |
| Onapristone | DRUG | Phase PHASE1 | Breast Cancer | WITHDRAWN | NCT06938711 |
| Questionnaire Administration | OTHER | Phase PHASE2 | Refractory Endometrial Adenocarcinoma | ACTIVE_NOT_RECRUITING | NCT04719273 |
| Quality-of-Life Assessment | OTHER | Phase PHASE2 | Refractory Endometrial Adenocarcinoma | ACTIVE_NOT_RECRUITING | NCT04719273 |
| Anastrozole | DRUG | Phase PHASE2 | Refractory Endometrial Adenocarcinoma | ACTIVE_NOT_RECRUITING | NCT04719273 |
| Extended-release Onapristone | DRUG | Phase PHASE2 | Refractory Endometrial Adenocarcinoma | ACTIVE_NOT_RECRUITING | NCT04719273 |
| Onapristone ER + Anastrozole | DRUG | Phase PHASE2 | Granulosa Cell Ovarian Cancer | COMPLETED | NCT03909152 |
| Onapristone ER | DRUG | Phase PHASE1 | Metastatic Breast Cancer | WITHDRAWN | NCT04872608 |